Since their explosion in popularity, GLP-1 medications like semaglutide (Ozempic, Wegovy) have created an unexpected nutritional reality: by dramatically reducing appetite, they make it hard to hit basic nutritional needs. Eat less, absorb less — protein, micronutrients, fiber.
The supplement industry has responded fast. Products making GLP-1-adjacent claims have grown at 124% CAGR in North America according to industry data. Some address real needs. Many are marketing opportunism.
Key takeaways
- 124% CAGR over 5 years for GLP-1-adjacent supplement products — North America leads at 83% of that growth
- Core nutritional risks on GLP-1s: protein deficit, lean mass loss, B12/iron/folate shortfalls, digestive slowdown
- Protein supplementation is the most evidence-backed priority — hitting 1.2-1.6g/kg/day with reduced appetite is genuinely hard
- Oral GLP-1 pills (FDA-approved late 2025) are opening the market far beyond injectable users
- Watch out: products claiming to «naturally mimic» GLP-1 effects — minimal evidence
Why GLP-1 medications create real nutritional gaps
A GLP-1 medication like injectable semaglutide typically reduces caloric intake by 30-40%. Someone who ate 2,000 calories a day might now eat 1,200-1,400. That's tight. That's tight for covering protein needs (minimum 1.2-1.6g/kg/day to preserve muscle), B vitamins, iron, folates, and enough fiber to offset the digestive slowdown GLP-1s often cause.
The unintended result: lean mass (muscle) loss alongside fat loss. Studies suggest up to 40% of weight lost on GLP-1 medications can come from muscle tissue — which degrades body composition and weakens long-term metabolic health. That's the core problem GLP-1 companion supplements claim to address.
What's evidence-backed vs. what's marketing
Protein — Priority 1 (strong evidence)
Hitting 1.2-1.6g of protein per kg of body weight with half your normal appetite is objectively difficult. A protein supplement — whey, casein, or plant-based — is the most validated supplementation for GLP-1 users. It preserves muscle mass, improves satiety, and helps maintain basal metabolism. The full protocol is here.
Creatine — Priority 2 (emerging evidence)
Creatine is establishing itself as the second supplement of choice for GLP-1 users. It preserves muscular strength during caloric restriction, protects brain function (relevant in prolonged hypocaloric periods), and has an exceptional safety profile. Standard dose of 3-5g/day applies.
B12, iron, folates — Priority 3 (logical)
Reduced food intake mechanically reduces micronutrient intake. Medical follow-up of GLP-1 users should include screening for these markers. A quality multivitamin or targeted supplements are often appropriate — but supplementing without baseline testing isn't recommended.
"Natural GLP-1 boosters" — lots of marketing, minimal evidence
An entire product category claims to «naturally stimulate GLP-1 production» — using berberine, psyllium fiber, or various extracts. Clinical data on these products is limited and effects have never approached those of medications. Not fraudulent, but expectations should be modest.
The 2026 market: 3 user profiles
The rollout of oral GLP-1 pills (FDA-approved late 2025) is massively expanding the addressable population. Where injections were limited to people with BMI > 30 under structured medical oversight, pills lower the barrier to entry. Three user profiles are emerging:
- Supervised medical users: endocrinologist follow-up, prescribed supplements, supervised exercise
- Self-directed informed users: doing the research, buying protein and creatine, lifting weights
- Opportunistic users: taking the medication without nutritional support or exercise — the highest-risk group for muscle loss
That third group is where GLP-1 companion supplement growth is strongest — and where the educational work is most needed.